We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ID 110. The Potential Effect of Ketapang (Terminalia cattapa) Leaf Extract as Co-chemotherapy Agent of Doxorubicin on Breast (T47D) and Cervix (HeLa) Cancer Cell Lines.
- Authors
S, Elza; N. S., Senja; S., Binaripan; A. N., Nunuk
- Abstract
Introduction: Doxorubicin is one of the chemotherapy agents frequently used for curing breast and cervix cancer. Unfortunately, it has a severe negative effect; it is necessary to have co-chemotherapy to reduce the adverse reaction. To improve the effectivity of doxorubicin, the development was done by combining it with the ethanolic extracts of the ketapang leaves. Objectives: The aim of this study was to determine the sensitivity of doxorubicin as a cytotoxic agent against T47D and HeLa cancer cells and their combination with ethanolic extracts of the ketapang leaves (EKL). Materials and Methods: The cytotoxic test was conducted using MTT assay with the concentration series of doxorubicin (0.625-40 nM for T47D and 0.5-6 µM for HeLa) and EKL (50-1000 µg/mL). The combination between doxorubicin and EKL was used for combination treatment on T47D and HeLa cells. The observation of proliferation employed a doubling time method. Results: The IC50 value of doxorubicin and EKL inhibited T47D is 158 nM and 30 µg/mL; and inhibited HeLa cell growth with IC50 3.4 µM and 640 µg/mL, respectively. The combination therapy of doxorubicin and EKL on T47D cell line resulted in a synergistic effect with a combination index (CI) 0.62; while on HeLa, combination of doxorubicin and EKL have cytotoxic effect with dose dependent manner. The treatment doxorubicin and EKL on the proliferation of T47D and HeLa cancer cell shown that EKL increase of the inhibitory effect of doxorubicin. Conclusion: EKL has more potential to be developed as co-chemotherapy on doxorubicin therapy in T47D than on the HeLa cell line.
- Subjects
DOXORUBICIN; CELL lines; CANCER cells; HELA cells; TERMINALIA; CERVICAL cancer; FEMALE reproductive organs
- Publication
Journal of Pharmacy & Bioallied Sciences, 2020, Vol 12, p890
- ISSN
0976-4879
- Publication type
Article